Ensysce Biosciences, Inc. (ENSC )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ENSC
- Company Ensysce Biosciences, Inc.
- Price $0.62
- Changes Percentage 57.77
- Change 0.23
- Day Low $0.57
- Day High $0.77
- Year High $5.55
- Year Low $0.31
- Market Cap $1,477,420
- Price Avg 50 EMA (D) $0.78
- Price Avg 200 EMA (D) $1.78
- Exchange NASDAQ
- Volume 142,473,068
- Average Volume 5,770,240
- Open $0.64
- Previous Close $0.4
- EPS -6.35
- PE -0.10
- Earnings Announcement 2026-03-26 12:00:00
- Shares Outstanding $2,370,700
Company brief: ENSYSCE BIOSCIENCES, INC. (ENSC )
- Healthcare
- Biotechnology
- Dr. D. Lynn Kirkpatrick Ph.D.
- https://www.ensysce.com
- US
- N/A
- 03-14-2018
- US2936024056
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
ENSC Corporation News
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
accessnewswire.com -- Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 25, 2026 / Ensy...